Literature DB >> 10924811

Differential effects of antisense oligodeoxynucleotides directed against g(zalpha) and g(oalpha) on antinociception produced by spinal opioid and alpha(2) adrenergic receptor agonists.

Farzana Karim1, Sandra C Roerig.   

Abstract

The present studies assessed the role of G(zalpha) and G(oalpha) in spinal alpha(2) adrenergic receptor agonist-induced antinociception, as well as in antinociceptive synergism between spinal morphine and clonidine. Mice were pretreated with a single intrathecal (i.t.) injection of artificial cerebrospinal fluid (ACSF), antisense oligodeoxynucleotide(s) (ODN) directed against G(zalpha) or G(oalpha), or nonsense ODN. After 48 h, the antinociceptive effects expressed as per cent maximal possible effect (% MPE) of either i.t. morphine alone, clonidine alone or coadministered morphine plus clonidine, were evaluated in the tail flick test. Antisense ODN to G(zalpha) attenuated clonidine- but not morphine-induced antinociception. The ED(50) (95% confidence interval) value for clonidine in ACSF pretreated mice was 6.3 (4.9-8.1) nmol, and in nonsense ODN pretreated mice, it was 4.2 (2.8-6.3) nmol. However, in the G(zalpha) antisense ODN pretreated mice, the highest dose clonidine tested (50 nmol) produced only 41+/-8.5% MPE. Antisense ODN to G(zalpha) also blocked antinociception produced by i.t. UK14, 304 (alpha(2) adrenergic receptor agonist) and [D-Pen(2), D-Pen(5)] enkephalin (DPDPE) (delta opioid receptor agonist), whereas it failed to attenuate i.t. Tyr-D-Ala-Gly-N-Me-Phe-Gly-ol (DAMGO)- (mu opioid receptor agonist) and U50-488 (kappa opioid receptor agonist) -induced antinociception. Pretreatment with antisense ODN to G(oalpha) attenuated both morphine and clonidine induced antinociception and did not affect synergism between the agonists. These results suggest that spinal G(o)alpha mediates antinociception produced by both clonidine and morphine while G(zalpha) mediates alpha(2) adrenergic and delta opioid receptor mediated antinociception, but not antinociception produced by mu or kappa opioid agonists.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10924811     DOI: 10.1016/S0304-3959(00)00279-7

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  6 in total

Review 1.  Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis.

Authors:  Carolyn A Fairbanks; Laura S Stone; George L Wilcox
Journal:  Pharmacol Ther       Date:  2009-04-23       Impact factor: 12.310

2.  Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine.

Authors:  Zhe Ding; Robert B Raffa
Journal:  Br J Pharmacol       Date:  2009-04-30       Impact factor: 8.739

3.  The effects of estrogen on the α2-adrenergic receptor subtypes in rat uterine function in late pregnancy in vitro.

Authors:  Judit Hajagos-Toth; Judit Bota; Eszter Ducza; Adrienn Csanyi; Zita Tiszai; Anna Borsodi; Reza Samavati; Sandor Benyhe; Robert Gaspar
Journal:  Croat Med J       Date:  2016-04-23       Impact factor: 1.351

4.  The effects of progesterone on the alpha2-adrenergic receptor subtypes in late-pregnant uterine contractions in vitro.

Authors:  Judit Hajagos-Tóth; Judit Bóta; Eszter Ducza; Reza Samavati; Anna Borsodi; Sándor Benyhe; Róbert Gáspár
Journal:  Reprod Biol Endocrinol       Date:  2016-06-14       Impact factor: 5.211

5.  Peripheral inflammatory injury alters the relative abundance of Gα subunits in the dorsal horn of the spinal cord and in the rostral ventromedial medulla of male rats.

Authors:  Anne-Sophie Wattiez; Roxanne Y Walder; Christopher M Sande; Stephanie R White; Donna L Hammond
Journal:  Mol Pain       Date:  2017 Jan-Dec       Impact factor: 3.395

6.  Adrenergic Agonists Bind to Adrenergic-Receptor-Like Regions of the Mu Opioid Receptor, Enhancing Morphine and Methionine-Enkephalin Binding: A New Approach to "Biased Opioids"?

Authors:  Robert Root-Bernstein; Miah Turke; Udaya K Tiruttani Subhramanyam; Beth Churchill; Joerg Labahn
Journal:  Int J Mol Sci       Date:  2018-01-17       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.